By Aaron Tallent
Results from a multicountry, phase 3 basket trial found that antiretroviral therapy (ART) based on dolutegravir (DTG; ViiV Healthcare) was superior to standard-of-care regimens in preventing treatment failure for children living with HIV-1, according to results of the ODYssEY trial.
“Dolutegravir-based therapy, used as either first- or second-line [ART], resulted in fewer treatment failures compared with medication combinations currently used as standard of care. Also,